Onspira Therapeutics, Inc.

640 Lee Road, Ste 117
Wayne, PA 19087

  • LinkedIn - Grey Circle
  • Twitter - Grey Circle

© 2018 Onspira Therapeutics. All rights reserved.

Breathing new life into a brighter tomorrow

About Onspira

ONSPIRA THERAPEUTICS is focused on the development of life-changing medicines to bring hope to patients suffering from rare pulmonary diseases. Our lead program is a novel, inhaled interleukin-1 alpha and beta (IL-1 𝛼 & β) receptor antagonist protein being advanced for the treatment of bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients. BOS is a significant, often fatal condition affecting thousands of patients around the world. Additional development programs will address BOS following hematopoietic stem cell transplantation (HSCT), BOS caused by chemical exposure, interstitial pulmonary fibrosis and cystic fibrosis.


August 14, 2018

FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans

Please reload

At Onspira, patients are at the core of our relentless pursuit of novel therapies for rare lung diseases